LDS/Medical Tests/NTRK Gene Fusion Panel (NTRK1, NTRK2, and NTRK3), Solid Tumors

NTRK Gene Fusion Panel (NTRK1, NTRK2, and NTRK3), Solid Tumors

The NTRK gene family (NTRK1, NTRK2, and NTRK3) encodes the tropomyosin receptor kinase (Trk) A, B, and C proteins, which mediate neuronal differentiation and survival by binding to neurotrophins (NGF, BDNF, and NT-3). Upon ligand binding, Trk receptors activate intracellular signaling cascades, including the MAPK/ERK, PI3K/AKT, and PLCγ pathways, leading to cell proliferation and differentiation.

Oncogenic NTRK gene fusions occur when the 3′ region of an NTRK gene, encoding the tyrosine kinase domain, becomes fused to the 5′ region of an unrelated gene. These fusions lead to ligand-independent activation of the kinase and downstream proliferative signaling. Such rearrangements can occur as either interchromosomal or intrachromosomal events, producing constitutively active fusion proteins that function as oncogenic drivers.

NTRK gene fusions are found across a wide spectrum of solid tumors, including secretory carcinoma of the breast and salivary glands, infantile fibrosarcoma, colorectal cancer, thyroid carcinoma, gliomas, and melanomas. Detection of these fusions is critical for selecting patients who may benefit from TRK inhibitor therapies, such as larotrectinib (Vitrakvi®) and entrectinib (Rozlytrek®), which have demonstrated overall response rates greater than 75% in fusion-positive cancers

  • Identifies tumors harboring actionable NTRK1/2/3 fusions that are likely to respond to TRK inhibitor therapy
  • Provides prognostic and therapeutic guidance for targeted precision oncology
  • Supports companion diagnostic and eligibility assessment for larotrectinib and entrectinib

Results are reported as Positive or Negative for NTRK gene fusions based on sequencing analysis:

Positive: NTRK1, NTRK2, or NTRK3 fusion detected, consistent with potential benefit from TRK inhibitor therapy.

Negative: No NTRK gene fusions detected, does not exclude other oncogenic mechanisms or low-level variants.

Clinical correlation with histopathologic and molecular findings is recommended.

Negative (NTRK fusion not detected)

Targeted polymerase chain reaction (PCR) followed by next-generation sequencing (NGS) for detection of translocations or gene fusions involving NTRK1, NTRK2, and NTRK3.

Formalin-fixed, paraffin-embedded (FFPE) tumor tissue.

Stability

FFPE is stable at room temperature for longer time.

Reflex testing with RNA-based NGS or Pan-TRK immunohistochemistry (IHC) may be performed for confirmation.
1-3 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login